$50 mil. to fix Stryker quality problems
This article was originally published in The Silver Sheet
Executive Summary
Stryker says it will spend at least $50 million a year "over the next few years" to resolve quality systems issues related to three FDA warning letters, Katherine Owen, the firm's VP for strategy and investor relations, said during a Sept. 3 presentation at the Thomas Weisel Partners Healthcare Conference in Boston. The company's biotech division received a letter in April citing quality system and compliance violations at its Hopkinton, Mass., facility ("The Silver Sheet" May 2008). That letter was Stryker's third since March 2007; the other two came following FDA inspections of the firm's Mahwah, N.J., and Carrigtwohill, Ireland, plants
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.